National University of Singapore

Reusable, foldable and sterilisable ‘shield’ developed by NUS-NUH team provides additional protection for healthcare workers caring for COVID-19 patients

Research team took less than two months to come up with the portable Droplet and Aerosol Reducing Tent (DART), which lessens the risk of infection and is easy to sterilise
25-Jun-2020 7:10 AM EDT, by National University of Singapore

Newswise — A team of researchers from the National University of Singapore (NUS) has invented a foldable tent-like device that serves as a physical shield to reduce the risk of exposure to pathogens for healthcare workers performing droplet and aerosol generating procedures on COVID-19 patients. Known as the Droplet and Aerosol Reducing Tent (DART), the device was designed in collaboration with doctors from the National University Hospital (NUH). 

The DART can lessen the risks of infection associated with procedures such as suctioning, intubation and extubation by providing an extra layer of protection between the healthcare workers and the patient. It also helps to limit environmental contamination, which can be a source of transmission. 

The NUS team was led by Professor Freddy Boey, NUS Deputy President (Innovation & Enterprise), and Associate Professor Yen Ching-Chiuan, Co-Director of the Keio-NUS CUTE Center. The team comprises Dr Alfred Chia from NUS Department of Biomedical Engineering, Mr Eason Chow from Keio-NUS CUTE Center, doctoral student Mr Raymond Hon from the NUS Division of Industrial Design as well as researchers from the NUS Faculty of Engineering. The NUS team worked with Dr Deborah Khoo, Dr Wong Weng Hoa, Associate Professor Ti Lian Kah and Associate Professor Sophia Ang from the NUH Department of Anaesthesia. The multi-disciplinary team took less than two months to develop DART and validate its performance. 

“The quick invention and deployment of DART was made possible through a close collaboration between the NUS and NUH teams, which allowed multiple refinements to be made to the prototypes within a very short time. The NUS team was able to come up with the various designs while adhering to the restrictions of the circuit breaker period, and found different ways to address design and performance related challenges when many resources were not available. The NUH team was instrumental in testing our prototypes in a clinical setting, allowing us to interactively and rapidly refine the performance of the device,” shared Prof Boey. 

Extra protection for frontline healthcare workers

The COVID-19 pandemic dramatically increased the need for infection control when intubating patients. Intubation is the placement of a flexible plastic tube into the windpipe to maintain an open airway or to serve as a conduit through which to administer certain drugs. The removal of this plastic tube is known as extubation. These are risky procedures that may put healthcare workers in danger of becoming infected. 

Evidence from the Severe Acute Respiratory Syndrome (SARS) outbreak in 2003 showed that healthcare workers involved in intubation were more likely to contract the disease compared with those who did not. This risk has similar implications for the current coronavirus outbreak, affecting anaesthesiologists, operating theatre staff, intensive care unit staff, and even first responders who are required to intubate collapsed patients in the COVID-19 general ward. 

Dr Khoo, a Consultant at the NUH Department of Anaesthesia, said, “Healthcare workers caring for patients run the risk of being exposed to known, suspected, or even asymptomatic COVID-19 patients. The DART serves as an additional physical barrier to infection and provides enhanced protection for healthcare staff at a time when they need it the most, giving us greater peace of mind and enabling care to continue safely for both patients and healthcare workers in the hospitals.” 

Practical and versatile solution 

The DART is a portable, tent-like structure that that can be placed around the patient’s head when intubating or extubating. It weighs three kilograms, and can be folded into a flat structure measuring around 51 centimetres by 55 centimetres, with a thickness of three centimetres, making it easy to transport, store and sterilise. It is also simple and fast to set up.   

The device features transparent polycarbonate panels, 3D printed nylon joints and Delrin inserts. These durable materials were chosen by the NUS team to enable the device to be sterilised by all standard forms of decontamination used in hospitals, such as elevated temperature autoclaving, and using alcohol of 70 per cent concentration. This facilitates the reusability of the device, and eliminates the risk of cross-contamination. 

Arm access ports are situated on the back and side panels of the device. The snap-on flanges allow the attachment of disposable sleeves or diaphragms. This addresses the concern of the arm ports being high risk areas of contamination, and gives the healthcare workers the option to use either sleeved or diaphragm seals – materials easily available in hospitals – according to their preference. The elliptical shape of the access ports gives the user more leeway for arm movements and to manoeuvre, which are important in handling the patient. 

A key feature of the DART is its ability to direct air within itself through a High Efficiency Particulate Air (HEPA) filter. It has a set of connectors that enables suction from a central vacuum system, or by a battery-operated fan attached to a HEPA filter. The negative pressure generated reduces leakage of exhaled aerosols or droplets from the patient out of the confines of the DART. 

Preliminary findings by the research team showed that the DART performs its barrier function as designed, and the exhaust function via the HEPA filter gives additional assurance to the user. 

Prototype testing in Singapore hospitals 

The research team has produced 25 prototypes which are being tested in different departments and hospitals of the National University Health System (namely NUH, Ng Teng Fong General Hospital and Alexandra Hospital), Tan Tock Seng Hospital, Changi General Hospital, Thomson Medical Centre, and several private hospitals operated by Parkway Hospitals Singapore.   

The team is looking to swiftly refine the DART based on the feedback provided by different medical departments, and hopes to provide the device as a form of medical aid to Singapore hospitals as well as hospitals in the region. The team will be partnering Temasek Foundation to distribute the DART, complementing its donation of ventilators to the region.  

The DART is one of the innovations developed by NUS and NUH to tackle pressing issues that healthcare workers face in the current global pandemic. 

Since the start of the crisis, NUS has been proactively participating in the fight against COVID-19 on different fronts, with research ranging from rapid diagnostics to case connections and vaccine development, as well as harnessing information and technology solutions to explore everything from modelling public health to fighting false rumours online. NUH has also been on the front line of the battle against COVID-19, as a tertiary hospital that has treated more than 900 COVID-19 patients to date.    

Filters close

Showing results

110 of 2816
access_time Embargo lifts in 2 days
Embargo will expire: 6-Aug-2020 11:00 AM EDT Released to reporters: 5-Aug-2020 4:25 PM EDT

A reporter's PressPass is required to access this story until the embargo expires on 6-Aug-2020 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded uab-department-of-pathology-develops-strategy-to-support-guidesafe-entry-testing-process-more-than-200-000-samples
Released: 5-Aug-2020 4:10 PM EDT
UAB Department of Pathology develops strategy to support GuideSafe™ Entry Testing, process more than 200,000 samples
University of Alabama at Birmingham

This strategy will allow for ramping up testing capacity tenfold for the next 20-plus days leading up to the start of school.

Newswise: 239458_web.jpg
Released: 5-Aug-2020 2:50 PM EDT
New findings on enzymes with important role in SARS-CoV-2 infection
Uppsala University

Researchers at Uppsala University have described the presence, throughout the human body, of the enzyme ACE2.

Newswise: Button Project Lets Children See the Faces Behind the Masks
Released: 5-Aug-2020 2:50 PM EDT
Button Project Lets Children See the Faces Behind the Masks
Vanderbilt University Medical Center

When COVID-19 cases began rising in Nashville, masking became a regular part of life across Vanderbilt University Medical Center and Children’s Hospital as one of several public health safety measures to protect employees and patients from potential COVID-19 exposure. Children’s Hospital decided to get creative to ensure that the 1,700 children and families who visit the hospital and clinics each day can see that the same friendly faces they’ve always known still exist behind the masks.

Newswise: 239490_web.jpg
Released: 5-Aug-2020 1:45 PM EDT
Massey scientist suggests COVID-19 should be treated as an acute inflammatory disease
Virginia Commonwealth University (VCU)

The COVID-19 pandemic has had detrimental effects on global infrastructure sectors, including economic, political, health care, education and research systems, and there is still no definitive treatment strategy for the disease.

Newswise: Helping protect medical professionals
Released: 5-Aug-2020 1:05 PM EDT
Helping protect medical professionals
Sandia National Laboratories

A media comprised of a sandwich of materials, tested by Sandia National Laboratories, is being manufactured into N95-like respirators that could be used in local medical facilities. The project originated from the urgent need for personal protective equipment when the COVID-19 outbreak began.

Released: 5-Aug-2020 12:50 PM EDT
UCI scientists get ‘initial hit’ in developing drug to treat COVID-19
University of California, Irvine

Irvine, Calif., Aug. 5, 2020 – When the coronavirus pandemic hit, almost everyone at the University of California, Irvine – and colleges across the nation – had to abandon campus. But James Nowick, professor of chemistry, was not a part of that exodus. That’s because his lab, which designs and constructs chemical molecules, had the right equipment to help in the global push to find treatments for COVID-19.

Showing results

110 of 2816